Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CGC
CGC logo

CGC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.060
Open
1.040
VWAP
1.03
Vol
17.88M
Mkt Cap
466.21M
Low
1.000
Amount
18.48M
EV/EBITDA(TTM)
198.92
Total Shares
448.28M
EV
514.20M
EV/OCF(TTM)
--
P/S(TTM)
1.18
Canopy Growth Corporation is a cannabis company, which produces, distributes, and sells a diverse range of cannabis and cannabis-related products for both adult-use and medical purposes. The Company brands include tweed, DOJA, LivRelief Infused, Deep Space, Ace Valley, 7ACRES, Vert, Twd, Wana, Hiway and Canopy Medical. The LivRelief Infused is transdermal creams contain a delivery system designed to penetrate a range of cannabidiol (CBD) and tetrahydrocannabinol (THC). The Deep Space offers beverages and gummies, containing the THC potency available in the Canadian market. The Ace Valley is a cannabis brand focused on ready-to-enjoy beverages. The 7ACRES offers products that are crafted by cannabis enthusiasts. The Wana gummies are created with a handcrafted recipe made with pectin, not gelatin, creating a gluten-free shelf-stable recipe that doesn’t melt. Its Canopy Medical is a pharmaceutical manufacturer for the production, import and release of medical cannabis products in Germany.
Show More

Events Timeline

(ET)
2026-04-08
08:50:00
Significant Increases in Indicative Borrow Rates for Liquid Options
select
2026-03-31 (ET)
2026-03-31
07:40:00
Canopy Growth Launches New Cannabis Brand Deelish
select
2026-03-27 (ET)
2026-03-27
07:40:00
Canopy Growth Appoints David Manner as Managing Director of Storz & Bickel
select
2026-03-19 (ET)
2026-03-19
11:20:00
Representative Proposes Bill to Protect Legal Cannabis Businesses
select
link
2026-02-13 (ET)
2026-02-13
08:50:00
Largest Indicative Borrow Rate Increases in Liquid Options
select
2026-02-06 (ET)
2026-02-06
16:30:00
Canopy Growth Files to Sell 18.71M Common Shares
select
2026-02-06
08:50:00
Significant Increases in Borrow Rates Among Liquid Option Names
select

News

Newsfilter
5.0
03-31Newsfilter
Canopy Growth Launches New Brand Deelish for Everyday Consumers
  • Brand Launch: Canopy Growth has introduced a new brand, Deelish, designed for everyday consumers, offering flower with 27%-33% THC and pre-rolls with 26%-32% THC, aimed at meeting the demand for high-potency products in the market.
  • Product Diversity: The Deelish product line includes four SKUs across various formats, such as 28g Whole Flower and 2x1g pre-rolls, ensuring consumers have access to a diverse range of options, thereby enhancing brand appeal.
  • Market Positioning: Focused on the value segment, CEO Luc Mongeau stated that Deelish aims to deliver high-potency products at reasonable prices to align with consumer shopping habits, reflecting the evolving trends in the market.
  • Regional Availability: Currently, Deelish products are available at select stores across Ontario and Alberta, marking Canopy Growth's further expansion in the Canadian market and strengthening its position in a competitive landscape.
Fool
2.0
03-30Fool
Canopy Growth Stock Continues to Decline
  • Stock Price Decline: Canopy Growth's stock has dropped 27% this year and is trading near its 52-week low, indicating ongoing struggles in a highly competitive market that have severely undermined investor confidence.
  • Profitability Challenges: In the last quarter of 2025, the company reported net revenue of CAD 74.5 million, flat year-over-year, while operating losses increased from CAD 23.8 million to CAD 26.4 million, highlighting difficulties in cost management.
  • Bleak Market Outlook: Despite legalization in Canada, Canopy Growth faces significant challenges in achieving profitability due to fierce competition and market restrictions, with its stock plummeting over 99% in the past five years, leading to a pessimistic outlook from investors.
  • Hope for Legal Reform: The company's future hinges on the potential legalization of marijuana in the U.S., which could open up substantial market opportunities, but this prospect remains distant, prompting investors to approach with caution.
NASDAQ.COM
9.5
03-30NASDAQ.COM
Canopy Growth Faces Pressure as U.S. Marijuana Legalization Remains Unlikely
  • Stock Price Decline: Canopy Growth's stock has dropped 27% this year and is trading near its 52-week low, reflecting severe investor pessimism about its future prospects and resulting in a significant loss of confidence.
  • Poor Financial Performance: In the last three months of 2025, the company reported net revenue of CAD 74.5 million, flat year-over-year, while incurring an operating loss of CAD 26.4 million, which is higher than the CAD 23.8 million loss from the previous year, indicating a continued deterioration in profitability.
  • Intense Market Competition: Although marijuana is legalized in Canada, Canopy Growth faces fragmentation and low margins due to fierce competition and market restrictions, making it difficult for the company to dominate the industry.
  • Bleak Future Outlook: With hopes for marijuana legalization in the U.S. appearing dim, Canopy Growth's market cap stands at around $380 million, a stark decline from over $12 billion five years ago, prompting investors to carefully consider their positions in the stock.
Newsfilter
8.5
03-30Newsfilter
Apollo Named Best Medical Cannabis Clinic by Toronto Star Readers' Choice Awards
  • Patient Trust Recognition: Apollo Cannabis Clinics has been voted Best Medical Cannabis Clinic in the 2025 Toronto Star Readers' Choice Awards, reflecting the high level of trust patients place in its care, thereby reinforcing Canopy Growth's leadership in the medical cannabis sector.
  • Accessible Medical Services: Apollo offers free virtual medical cannabis consultations nationwide without referral requirements, providing personalized treatment plans and ongoing support, which has helped thousands of Canadians manage chronic pain, anxiety, and other complex conditions.
  • CEO's Commitment: Canopy Growth CEO Luc Mongeau emphasized that the recognition of Apollo stems from a genuine commitment to positive patient outcomes, making this trust strategically significant for the company's future business development.
  • Innovative Products and Services: Canopy Growth delivers innovative products through various owned brands, and Apollo's success not only enhances brand image but also lays a foundation for the company's expansion in the medical cannabis market, showcasing its determination to improve patients' quality of life.
Newsfilter
5.0
03-27Newsfilter
David Männer Appointed Managing Director of Storz & Bickel
  • Leadership Transition: David Männer will succeed Jürgen Bickel as Managing Director of Storz & Bickel effective April 1, 2026, following Bickel's 25 years of transformative leadership that established the company as a global leader in vaporization technology, indicating stability and continuity in the company's leadership.
  • Industry Benchmark: Since its founding in 2001, Storz & Bickel has set the standard for innovation, product quality, and design, earning ISO 13485 certification and the Dr. Rudolf Eberle Prize, which underscores its strong competitive position in the market as a benchmark for vapor quality.
  • Future Development: Incoming Managing Director Männer, a 14-year veteran of the company with deep operational knowledge and leadership skills, is expected to continue driving the company's expansion in the U.S. market and innovation efforts, further solidifying Storz & Bickel's market position.
  • Strategic Vision: Canopy Growth CEO Luc Mongeau stated that Männer's appointment will accelerate Storz & Bickel's growth, reflecting the company's ambitions in the global vaporization market and aiming to enhance brand influence through ongoing innovation.
Fool
9.5
03-21Fool
Canopy Growth and Sarepta Face Dismal Prospects
  • Canopy Growth's Financial Struggles: In Q3 of fiscal 2026, Canopy Growth reported flat net revenue of CA$75 million ($54.6 million) year-over-year, with a 49% improvement in the bottom line overshadowed by a net loss per share of CA$0.18 ($0.13), indicating ongoing financial distress.
  • Regulatory Challenges in Cannabis: The cannabis industry is fraught with heavy regulation and uncertainty, making future legal changes and market responses unpredictable, which casts a shadow over Canopy Growth's prospects and warrants caution from investors.
  • Sarepta Therapeutics' Drug Risks: Sarepta's Elevidys drug has faced significant challenges after causing the deaths of two patients due to liver failure; despite remedial actions, the company's Q4 2025 revenue fell 33% year-over-year to $442.9 million, reflecting worsening financial conditions.
  • Clinical Trial Failures: As Sarepta seeks full approval for other DMD drugs, recent confirmatory trial results have failed to meet primary endpoints, exacerbating investor concerns about its future, with the stock plummeting 79% over the past year.
Wall Street analysts forecast CGC stock price to rise
4 Analyst Rating
Wall Street analysts forecast CGC stock price to rise
1 Buy
2 Hold
1 Sell
Hold
Current: 0.000
sliders
Low
1.03
Averages
2.52
High
5.90
Current: 0.000
sliders
Low
1.03
Averages
2.52
High
5.90
Canaccord
Buy
initiated
$2
AI Analysis
2026-03-27
Reason
Canaccord
Price Target
$2
AI Analysis
2026-03-27
initiated
Buy
Reason
Canaccord initiated coverage of Canopy Growth with a Buy rating and C$2 price target. Canopy is a leading cannabis company producing, distributing, and selling a "diverse range" of cannabis and cannabis-related products in key, global adult-use and medical cannabis markets, the analyst tells investors in a research note. The firm says the company's pivot from an asset-light, third-party supply model to an asset-right, in-house supply model will improve its global competitive positioning.
Alliance Global
Aaron Grey
Neutral
downgrade
2026-02-06
Reason
Alliance Global
Aaron Grey
Price Target
2026-02-06
downgrade
Neutral
Reason
Alliance Global analyst Aaron Grey lowered the firm's price target on Canopy Growth to C$1.80 from C$2.50 and keeps a Neutral rating on the shares following the fiscal Q3 report. The firm reduced the stock's multiple to reflect the potential impact from changes to veteran reimbursement and uncertainty around its gross margins.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CGC
Unlock Now

Valuation Metrics

The current forward P/E ratio for Canopy Growth Corp (CGC.O) is 20.37, compared to its 5-year average forward P/E of -2.54. For a more detailed relative valuation and DCF analysis to assess Canopy Growth Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.54
Current PE
20.37
Overvalued PE
14.86
Undervalued PE
-19.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-279.93
Current EV/EBITDA
-13.63
Overvalued EV/EBITDA
443.67
Undervalued EV/EBITDA
-1003.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.56
Current PS
1.25
Overvalued PS
9.51
Undervalued PS
-0.39

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

top 5 penny stocks?
Intellectia · 91 candidates
Market Cap: 50.00M - 2.00BRegion: USPrice: $0.10 - $5.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Month Price Change Pct: $0.00 - $150.00Monthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
RXT logo
RXT
Rackspace Technology Inc
409.23M
KOS logo
KOS
Kosmos Energy Ltd
1.03B
IOVA logo
IOVA
Iovance Biotherapeutics Inc
1.14B
GERN logo
GERN
Geron Corp
1.20B
TRX logo
TRX
TRX Gold Corp
516.12M
AQST logo
AQST
Aquestive Therapeutics Inc
481.91M
Should I Buy cannabis stocks?
Intellectia · 9 candidates
Market Cap: >= 50.00MThemes: The Cannabis IndustryList Exchange: XNYS, XNASMonthly Average Dollar Volume: >= 100,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
4.06B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.29B
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
CGC logo
CGC
Canopy Growth Corp
440.50M
SNDL logo
SNDL
SNDL Inc
386.25M
cannabis
Intellectia · 8 candidates
Market Cap: >= 200.00MPrice: >= $1.00Themes: The Cannabis IndustryIs Optionable: TrueMonthly Average Dollar Volume: >= 200,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
4.06B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.29B
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
CGC logo
CGC
Canopy Growth Corp
440.50M
SNDL logo
SNDL
SNDL Inc
386.25M
stocks under $2 for day trade today
Intellectia · 158 candidates
Price: <= $2.00Volume: >= 500,000Price Change Pct: $-5.00 - $20.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
PHIO logo
PHIO
Phio Pharmaceuticals Corp
12.06M
PLUG logo
PLUG
Plug Power Inc
2.84B
BURU logo
BURU
NUBURU Inc
56.42M
TIRX logo
TIRX
Tian Ruixiang Holdings Ltd
10.04M
JTAI logo
JTAI
Jet.AI Inc
5.61M
BTBT logo
BTBT
Bit Digital Inc
563.19M
marijuana stocks
Intellectia · 8 candidates
Market Cap: >= 200.00MRegion: US, CanadaPrice: >= $1.00Themes: The Cannabis IndustryList Exchange: XNYS, XNAS, XASEIs Optionable: TrueMonthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
3.70B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.41B
TLRY logo
TLRY
Tilray Brands Inc
1.01B
CRON logo
CRON
Cronos Group Inc
999.35M
CGC logo
CGC
Canopy Growth Corp
460.70M
SNDL logo
SNDL
SNDL Inc
406.85M
stocks to buy for 1.19 i only have $10
Intellectia · 105 candidates
Price: <= $1.19Weekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ASST logo
ASST
Strive Inc
1.11B
UP logo
UP
Wheels Up Experience Inc
624.57M
CAN logo
CAN
Canaan Inc
498.64M
CGC logo
CGC
Canopy Growth Corp
460.70M
DVLT logo
DVLT
Datavault AI Inc
433.82M
BYND logo
BYND
Beyond Meat Inc
424.50M
show me some penny stocks
Intellectia · 417 candidates
Market Cap: <= 500.00MPrice: <= $5.00Weekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
CAN logo
CAN
Canaan Inc
498.64M
LX logo
LX
Lexinfintech Holdings Ltd
498.06M
THM logo
THM
International Tower Hill Mines Ltd
494.77M
ORGO logo
ORGO
Organogenesis Holdings Inc
487.34M
GEVO logo
GEVO
Gevo Inc
487.04M
CLNE logo
CLNE
Clean Energy Fuels Corp
486.85M
Top cannabis stocks to buy
Intellectia · 9 candidates
Market Cap: >= 50.00MRevenue Ttm: >= 10.00MThemes: The Cannabis Industry
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
3.70B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.41B
TLRY logo
TLRY
Tilray Brands Inc
1.01B
CRON logo
CRON
Cronos Group Inc
999.35M
CGC logo
CGC
Canopy Growth Corp
460.70M
SNDL logo
SNDL
SNDL Inc
406.85M

Whales Holding CGC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Canopy Growth Corp (CGC) stock price today?

The current price of CGC is 1.04 USD — it has increased 4.84

What is Canopy Growth Corp (CGC)'s business?

Canopy Growth Corporation is a cannabis company, which produces, distributes, and sells a diverse range of cannabis and cannabis-related products for both adult-use and medical purposes. The Company brands include tweed, DOJA, LivRelief Infused, Deep Space, Ace Valley, 7ACRES, Vert, Twd, Wana, Hiway and Canopy Medical. The LivRelief Infused is transdermal creams contain a delivery system designed to penetrate a range of cannabidiol (CBD) and tetrahydrocannabinol (THC). The Deep Space offers beverages and gummies, containing the THC potency available in the Canadian market. The Ace Valley is a cannabis brand focused on ready-to-enjoy beverages. The 7ACRES offers products that are crafted by cannabis enthusiasts. The Wana gummies are created with a handcrafted recipe made with pectin, not gelatin, creating a gluten-free shelf-stable recipe that doesn’t melt. Its Canopy Medical is a pharmaceutical manufacturer for the production, import and release of medical cannabis products in Germany.

What is the price predicton of CGC Stock?

Wall Street analysts forecast CGC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGC is2.52 USD with a low forecast of 1.03 USD and a high forecast of 5.90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Canopy Growth Corp (CGC)'s revenue for the last quarter?

Canopy Growth Corp revenue for the last quarter amounts to 74.54M USD, decreased -0.29

What is Canopy Growth Corp (CGC)'s earnings per share (EPS) for the last quarter?

Canopy Growth Corp. EPS for the last quarter amounts to -0.18 USD, decreased -83.78

How many employees does Canopy Growth Corp (CGC). have?

Canopy Growth Corp (CGC) has 960 emplpoyees as of April 09 2026.

What is Canopy Growth Corp (CGC) market cap?

Today CGC has the market capitalization of 466.21M USD.